Viridian Therapeutics price to sales ratio VRDN

Market value divided by revenue over the last twelve months, since 2015.

Today, Oct 23, 2026: 35.6×
10-year median: 30.9×
Against its 10-year history: 54th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.8× to 199×
Peer median: 2.2×

Viridian Therapeutics' price to sales ratio is 35.6× as of Oct 23, 2026.

That is above its ten-year median of 30.9×, close to the middle of its last ten years.

Over that time it ranged from 0.8× in Nov 2016 to 199× in Jul 2022.

The median for 10 large drugmakers of a similar size is 2.2×.

Price to sales ratio over time

median 30.9×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	35.6×	19.4×	44.8×
2025	43.0×	37.0×	43.6×
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	199×	89.0×	199×
2021	153×	33.5×	167×
2020	34.3×	4.2×	41.6×
2019	4.0×	3.6×	21.9×
2018	9.1×	8.1×	56.9×
2017	65.2×	1.1×	107×
2016	1.1×	0.8×	2.9×
2015	3.1×	1.8×	4.5×

Against its peers

Companies in Drug Manufacturers - General nearest Viridian Therapeutics' size, closest first, today.

Company	Price to sales ratio
VRDNViridian Therapeutics	35.6×
NRIXNurix Therapeutics	3.9×
PBHPrestige Consumer Healthcare	2.0×
HRMYHarmony Biosciences	2.2×
OGNOrganon	0.6×
LQDALiquidia	8.5×
ANIPANI Pharmaceuticals	1.7×
ARQTArcutis Biotherapeutics	8.5×
INDVIndivior Pharmaceuticals	3.1×
PAHCPhibro Animal Health	1.0×
ANABAnaptysbio	n/m
Peer median	2.2×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Viridian Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.